MedTrace Logo

Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension

NCT01631227 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 665

Last updated 2014-07-25

Study results available
· View outcomes & findings →

Summary

Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy. The new formulation is compared to the currently marketed eprosartan tablet. Equivalent efficacy in blood pressure lowering effects should be demonstrated.

Conditions

  • Essential Hypertension

Interventions

DRUG

Eprosartan

Eprosartan 450 mg

DRUG

Eprosartan Mesylate

Eprosartan mesylate 600 mg

DRUG

Placebo Eprosartan mesylate

Placebo Eprosartan mesylate

DRUG

Placebo Eprosartan

Placebo Eprosartan

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • Synexus

    collaborator OTHER

  • author! et al. BV

    collaborator UNKNOWN

  • Abbott

    lead INDUSTRY

Principal Investigators

  • Dmitri N. Kazei, MD · Abbott Healthcare Products B.V.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Germany
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01631227 on ClinicalTrials.gov